|
🐜
|
Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.
59 auth.
T. Weismüller,
P. Trivedi,
A. Bergquist,
M. Imam,
H. Lenzen,
C. Ponsioen,
K. Holm,
D. Gotthardt,
M. Färkkilä,
H. Marschall,
D. Thorburn,
R. Weersma,
J. Fevery,
T. Mueller,
O. Chazouilleres,
...
K. Schulze,
K. Lazaridis,
S. Almér,
S. Pereira,
C. Levy,
A. Mason,
S. Naess,
C. Bowlus,
A. Floreani,
E. Halilbasic,
Kidist K. Yimam,
P. Milkiewicz,
U. Beuers,
D. Huynh,
A. Parés,
C. Manser,
G. Dalekos,
B. Eksteen,
P. Invernizzi,
C. Berg,
G. Kirchner,
C. Sarrazin,
V. Zimmer,
L. Fabris,
F. Braun,
M. Marzioni,
B. Juran,
K. Said,
C. Rupp,
K. Jokelainen,
Maria Benito de Valle,
F. Saffioti,
A. Cheung,
M. Trauner,
C. Schramm,
R. Chapman,
T. Karlsen,
E. Schrumpf,
C. Strassburg,
M. Manns,
K. Lindor,
G. Hirschfield,
B. Hansen,
K. Boberg
|
8 |
2017 |
8
🐜
|
|
🐜
|
Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis
13 auth.
I. Engels,
Anna Stępczyńska,
C. Stroh,
K. Lauber,
C. Berg,
Ralf Schwenzer,
H. Wajant,
R. Jänicke,
A. Porter,
C. Belka,
...
M. Gregor,
K. Schulze-Osthoff,
S. Wesselborg
|
8 |
2000 |
8
🐜
|
|
🐬
|
Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis
H. Bantel,
C. Berg,
M. Vieth,
M. Stolte,
W. Kruis,
K. Schulze-Osthoff
|
7 |
2000 |
7
🐬
|
|
🐜
|
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
25 auth.
J. Dietz,
S. Susser,
J. Vermehren,
K. Peiffer,
G. Grammatikos,
A. Berger,
P. Ferenci,
M. Buti,
B. Müllhaupt,
B. Hunyady,
H. Hinrichsen,
S. Mauss,
J. Petersen,
P. Buggisch,
G. Felten,
...
D. Hüppe,
G. Knecht,
T. Lutz,
E. Schott,
C. Berg,
U. Spengler,
T. von Hahn,
T. Berg,
S. Zeuzem,
C. Sarrazin
|
6 |
2017 |
6
🐜
|
|
🐜
|
Granulocyte-Colony Stimulating Factor (G-CSF) to treat acute-on-chronic liver failure, a multicenter randomized trial (GRAFT study).
27 auth.
C. Engelmann,
A. Herber,
A. Franke,
Tony Bruns,
I. Schiefke,
A. Zipprich,
S. Zeuzem,
T. Goeser,
A. Canbay,
C. Berg,
J. Trebicka,
F. Uschner,
Johannes Chang,
T. Mueller,
Niklas F. Aehling,
...
M. Schmelzle,
Katrin Splith,
F. Lammert,
C. Lange,
C. Sarrazin,
C. Trautwein,
M. Manns,
D. Häussinger,
J. Pfeiffenberger,
P. Galle,
A. Schmiedeknecht,
T. Berg
|
6 |
2021 |
6
🐜
|
|
🐜
|
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection
30 auth.
R. Fontana,
Robert S. Brown,
A. Moreno-Zamora,
M. Prieto,
Shobha N. Joshi,
M. Londoño,
K. Herzer,
K. Chacko,
R. Stauber,
V. Knop,
S. Jafri,
L. Castells,
P. Ferenci,
C. Torti,
C. Durand,
...
L. Loiacono,
R. Lionetti,
R. Bahirwani,
O. Weiland,
Abdullah Mubarak,
A. Elsharkawy,
B. Stadler,
M. Montalbano,
C. Berg,
A. Pellicelli,
S. Stenmark,
F. Vekeman,
R. Ionescu-Ittu,
B. Emond,
K. Reddy
|
6 |
2016 |
6
🐜
|
|
🐢
|
Telaprevir‐based triple therapy in liver transplant patients with hepatitis C virus: A 12‐week pilot study providing safety and efficacy data
7 auth.
C. Werner,
Daniel P. Egetemeyr,
U. Lauer,
S. Nadalin,
A. Königsrainer,
N. Malek,
...
C. Berg
|
6 |
2012 |
6
🐢
|
|
🐜
|
Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib
8 auth.
M. Horger,
U. Lauer,
C. Schraml,
C. Berg,
U. Koppenhöfer,
C. Claussen,
...
M. Gregor,
M. Bitzer
|
6 |
2009 |
6
🐜
|
|
🐢
|
Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12
7 auth.
C. Werner,
J. Schwarz,
Daniel P. Egetemeyr,
R. Beck,
N. Malek,
U. Lauer,
...
C. Berg
|
5 |
2016 |
5
🐢
|
|
🐜
|
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
24 auth.
C. Bowlus,
M. Galamboš,
R. Aspinall,
G. Hirschfield,
D. Jones,
Y. Dörffel,
S. Gordon,
S. Harrison,
A. Kremer,
M. Mayo,
...
P. Thuluvath,
C. Levy,
M. Swain,
G. Neff,
D. Sheridan,
C. Stanca,
C. Berg,
A. Goel,
M. Shiffman,
J. Vierling,
P. Boudes,
A. Steinberg,
Yun-Jung Choi,
Charles A. McWherter
|
5 |
2022 |
5
🐜
|
